169 related articles for article (PubMed ID: 34428740)
1. Metformin addition to androgen deprivation therapy effect on cancer prostate patients with type 2 diabetes.
Aboelnaga EM; Aboelnaga MM; Elkalla HM
Diabetes Metab Syndr; 2021; 15(5):102251. PubMed ID: 34428740
[TBL] [Abstract][Full Text] [Related]
2. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
Nobes JP; Langley SE; Klopper T; Russell-Jones D; Laing RW
BJU Int; 2012 May; 109(10):1495-502. PubMed ID: 21933330
[TBL] [Abstract][Full Text] [Related]
3. Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.
Richards KA; Liou JI; Cryns VL; Downs TM; Abel EJ; Jarrard DF
J Urol; 2018 Dec; 200(6):1256-1263. PubMed ID: 29940252
[TBL] [Abstract][Full Text] [Related]
4. Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer.
Ranasinghe WKB; Williams S; Ischia J; Wetherell D; Baldwin G; Shulkes A; Sengupta S; Bolton D; Patel O
BJU Int; 2019 May; 123 Suppl 5():36-42. PubMed ID: 31012989
[TBL] [Abstract][Full Text] [Related]
5. An Open-Label Pilot Study of Metformin as a Concomitant Therapy on Patients with Prostate Cancer Undergoing Androgen Deprivation Treatment.
Zhu W; Xu H; Ma J; Guo J; Xue W; Gu B; Sheng L; Yao X; Sun F; Gong J; Qiu W; Ding Q; Jiang H
Urol Int; 2017; 98(1):79-84. PubMed ID: 27684440
[TBL] [Abstract][Full Text] [Related]
6. Metformin for Prevention of Anthropometric and Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled Trial.
Usmani N; Ghosh S; Sanghera KP; Ong AD; Koul R; Dubey A; Ahmed S; Quon H; Yee D; Parliament M; Sivananthan G; Hunter W; Danielson B; Rowe L; McDonald M; Kim JO
Int J Radiat Oncol Biol Phys; 2023 Feb; 115(2):317-326. PubMed ID: 35907513
[TBL] [Abstract][Full Text] [Related]
7. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
[TBL] [Abstract][Full Text] [Related]
8. Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.
Mahalingam D; Hanni S; Serritella AV; Fountzilas C; Michalek J; Hernandez B; Sarantopoulos J; Datta P; Romero O; Pillai SMA; Kuhn J; Pollak M; Thompson IM
Oncotarget; 2023 Jun; 14():622-636. PubMed ID: 37335291
[TBL] [Abstract][Full Text] [Related]
9. Metformin use and hospital attendance-related resources utilization among diabetic patients with prostate cancer on androgen deprivation therapy: A population-based cohort study.
Lee YHA; Hui JMH; Chung CT; Liu K; Dee EC; Ng K; Tse G; Chan JSK; Ng CF
Cancer Med; 2023 Apr; 12(8):9128-9132. PubMed ID: 36734312
[TBL] [Abstract][Full Text] [Related]
10. Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A population-based study.
Lee YHA; Hui JMH; Chan JSK; Liu K; Dee EC; Ng K; Tang P; Tse G; Ng CF
Prostate; 2023 Jan; 83(1):119-127. PubMed ID: 36178848
[TBL] [Abstract][Full Text] [Related]
11. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality.
Spratt DE; Zhang C; Zumsteg ZS; Pei X; Zhang Z; Zelefsky MJ
Eur Urol; 2013 Apr; 63(4):709-16. PubMed ID: 23287698
[TBL] [Abstract][Full Text] [Related]
12. Metformin Has a Positive Therapeutic Effect on Prostate Cancer in Patients With Type 2 Diabetes Mellitus.
Chong RW; Vasudevan V; Zuber J; Solomon SS
Am J Med Sci; 2016 Apr; 351(4):416-9. PubMed ID: 27079349
[TBL] [Abstract][Full Text] [Related]
13. Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.
Atkins KM; Chen MH; Wu J; Renshaw AA; Loffredo M; Kantoff PW; Small EJ; D'Amico AV
Cancer; 2018 Apr; 124(7):1383-1390. PubMed ID: 29266181
[TBL] [Abstract][Full Text] [Related]
14. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study.
Garcia-Albeniz X; Chan JM; Paciorek A; Logan RW; Kenfield SA; Cooperberg MR; Carroll PR; Hernán MA
Eur J Cancer; 2015 May; 51(7):817-24. PubMed ID: 25794605
[TBL] [Abstract][Full Text] [Related]
15. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
16. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
17. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
18. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
Boevé LMS; Hulshof MCCM; Vis AN; Zwinderman AH; Twisk JWR; Witjes WPJ; Delaere KPJ; Moorselaar RJAV; Verhagen PCMS; van Andel G
Eur Urol; 2019 Mar; 75(3):410-418. PubMed ID: 30266309
[TBL] [Abstract][Full Text] [Related]
19. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
